Uncovering influence links in molecular knowledge networks to streamline personalized medicine  by Shin, Dmitriy et al.
Journal of Biomedical Informatics 52 (2014) 394–405Contents lists available at ScienceDirect
Journal of Biomedical Informatics
journal homepage: www.elsevier .com/locate /y jb inUncovering inﬂuence links in molecular knowledge networks to
streamline personalized medicinehttp://dx.doi.org/10.1016/j.jbi.2014.08.003
1532-0464/ 2014 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
⇑ Corresponding author at: University of Missouri, School of Medicine, Depart-
ment of Pathology and Anatomical Sciences, Columbia, MO 65212, United States.
Fax: +1 (573)884 4612.
E-mail address: shindm@health.missouri.edu (D. Shin).Dmitriy Shin a,c,⇑, Gerald Arthur a,c, Mihail Popescu b,c,d, Dmitry Korkin f, Chi-Ren Shyu c,e
aUniversity of Missouri, School of Medicine, Department of Pathology and Anatomical Sciences, Columbia, MO 65212, United States
bUniversity of Missouri, School of Medicine, Department of Health Management and Informatics, Columbia, MO 65212, United States
cUniversity of Missouri, Graduate School, MU Informatics Institute, Columbia, MO 65211, United States
dUniversity of Missouri, College of Engineering, Department of Computer Science, Columbia, MO 65211, United States
eUniversity of Missouri, College of Engineering, Department of Electrical and Computer Engineering, Columbia, MO 65211, United States
fWorcester Polytechnic Institute, Department of Computer Science, Department of Biology and Biotechnology, Department of Applied Math, Worcester, MA 01609, United States
a r t i c l e i n f o a b s t r a c tArticle history:
Received 28 March 2014
Accepted 8 August 2014
Available online 19 August 2014
Keywords:
RDF inference
Morphoproteomics
Systems pathology
Theranostics
Personalized medicineObjectives: We developed Resource Description Framework (RDF)-induced InﬂuGrams (RIIG) – an informat-
ics formalism to uncover complex relationships among biomarker proteins and biological pathways using
the biomedical knowledge bases. We demonstrate an application of RIIG in morphoproteomics, a thera-
nostic technique aimed at comprehensive analysis of protein circuitries to design effective therapeutic
strategies in personalized medicine setting.
Methods: RIIG uses an RDF ‘‘mashup’’ knowledge base that integrates publicly available pathway and
protein data with ontologies. To mine for RDF-induced Inﬂuence Links, RIIG introduces notions of RDF
relevancy and RDF collider, which mimic conditional independence and ‘‘explaining away’’ mechanism in
probabilistic systems. Using these notions and constraint-based structure learning algorithms, the for-
malism generates the morphoproteomic diagrams, which we call InﬂuGrams, for further analysis by
experts.
Results: RIIG was able to recover up to 90% of predeﬁned inﬂuence links in a simulated environment
using synthetic data and outperformed a naïve Monte Carlo sampling of random links. In clinical cases
of Acute Lymphoblastic Leukemia (ALL) and Mesenchymal Chondrosarcoma, a signiﬁcant level of concor-
dance between the RIIG-generated and expert-built morphoproteomic diagrams was observed. In a clin-
ical case of Squamous Cell Carcinoma, RIIG allowed selection of alternative therapeutic targets, the validity
of which was supported by a systematic literature review. We have also illustrated an ability of RIIG to
discover novel inﬂuence links in the general case of the ALL.
Conclusions: Applications of the RIIG formalism demonstrated its potential to uncover patient-speciﬁc
complex relationships among biological entities to ﬁnd effective drug targets in a personalized medicine
setting. We conclude that RIIG provides an effective means not only to streamline morphoproteomic stud-
ies, but also to bridge curated biomedical knowledge and causal reasoningwith the clinical data in general.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction and background
Recent advances in ‘‘omics’’ technologies and decades of omics-
based research have resulted in generation of vast amounts of bio-
medical knowledge. This knowledge is expected to greatly improve
patient care by addressing disease complexity and heterogeneity in
the personalized medicine setting [1]. However, the complexityand fast growth of such knowledge make it intractable for the
majority of medical practitioners, thus undermining its practical
utility in medicine. Mental retention of large number of up-to-date
facts, ability to quickly retrieve the most relevant to the case infor-
mation and interpret inconsistencies of reported basic sciences dis-
coveries are big stumbling blocks on the way of effective utilization
of omics-derived knowledge at the bedside [2].
This phenomenon can be illustrated by an example from
medical ﬁelds of diagnostics and therapeutics, jointly known as
theranostics [3]. Over the last several decades, pathologists have
been using immunohistochemistry (IHC) [4] to identify expression
of aberrantly expressed disease-associated genes [4–8]. These
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from conﬁrming the presence of certain cell types to staging and
grading tumors and elucidating cancer phenotypes. Recently, it
was proposed to exploit IHC protein expression patterns on histo-
pathological slides to infer activation of molecular pathways and to
guide individual therapies [9]. The technique, termed as morpho-
proteomics, provides a more systemic picture of involved biological
mechanisms than traditional approaches. It can identify patient-
speciﬁc drug target candidates, predict susceptibility to small-
molecule inhibitors and explain resistance to conventional drug
treatments. The potential of morphoproteomics to improve thera-
peutics in a personalized medicine setting has been demonstrated
in a number of studies [9–27]. This method can now be viewed as
an implementation of the new medical paradigm of theranostics,
where approaches from diagnostics and therapeutics are merged
to produce better clinical outcomes.
There are, however, several obstacles in the way of widespread
acceptance of morphoproteomics. First, the current set of antibody
reagents routinely employed for IHC studies in the usual surgical
pathology laboratory to identify the presence of proteins and other
biomarkers in intra- and inter-cellular space is quite large. The
classic reference textbook, ‘‘Rosai and Ackerman’s Surgical Pathol-
ogy’’, brieﬂy describes the signiﬁcance of over 250 antigens useful
in general pathology and an additional 30 for hematopoietic dis-
eases. They recommend that the standard surgical pathology labo-
ratory be able to provide staining with approximately 90 antibody
reagents in house [28]. Assuming only two states of protein expres-
sion regardless of its cellular location, the expert analysis of all
possible combinations for even a half dozen of such proteins can
be very challenging (2^6 = 64 combinations). Second, as discussed
in [29], if one takes into account the cellular location of
protein expression (e.g. nuclear expression of phosphorylated
NF-kappa-B vs cytoplasmic) and consider more than just two
states of its expression, even a small increase in the number of
proteins in the study quickly would result in a combinatorial
explosion of the data that is hard to overcome. Reliable identiﬁca-
tion of the relevant pathways in this scenario is challenging
because each such protein expression pattern can manifest a dif-
ferent activation pattern of biological pathways. This all creates a
signiﬁcant barrier for pathologists to use morphoproteomics. A
comprehensive theranostic study in many cases is infeasible due
to limitations of individual practitioners’ knowledge of biological
processes. An inter-expert collaboration, while being able to
expand the knowledge space to a certain extent, is still not an
effective way to overcome this challenge. It is difﬁcult even for a
group of pathologists to recreate a more or less holistic picture of
activated pathways based on the clinical data.
One of the ways to overcoming the above-discussed problems is
to leverage biomedical knowledge stored in ‘‘omics’’ knowledge
bases (KB), a variety of which has been generated and made pub-
licly available. Data from the well-known sources of biological
information including pathways data from Reactome [30], BioCarta
[31], BioCyc [32], NCI PID [33], protein data from UniProt [34],
HPRD [35] can be obtained in Resource Description Framework
(RDF) format [36] directly from vendors’ website. In other cases,
data are available in XML format but can be readily transformed
into RDF using custom ontologies as it was done in [37]. There have
been a number of works showing the beneﬁts of Semantic Web
technologies to translational science and personalized medicine
[38–48] such as, for instance, logical language of RDF/N3 extension
[49–51].
Moreover, the development of comprehensive biomedical
ontologies made it possible to combine RDF data into so-called
integrated ‘‘mashup’’ knowledge bases. RDF-based query lan-
guages such as SPARQL [52] together with description logic andrule-based languages such as OWL [53] and SWRL [54] have been
shown to utilize the RDF ‘‘mashup’’ KBs to uncover complex rela-
tions among different types of biological entities to generate novel
hypotheses (for an example see [55]).
However, it might be challenging to use the ‘‘mashup’’ KBs
directly in personalized medicine setting and particularly in
morphoproteomics. While it is relatively trivial to utilize SPARQL
queries for retrieval of relevant biological facts, the results of such
one-at-a-time queries may still lack sufﬁcient explanatory power
for clinical decision-making. There is a need for a methodology that
will allow generation of a mechanistic picture of biological processes
that explains clinical ﬁndings and ﬁts all pieces of the puzzle
together. To address these challenges, we have developed RDF-
induced InﬂuGrams (RIIG), a novel informatics formalism that gen-
erates morphoproteomics diagrams by mining an RDF ‘‘mashup’’
knowledge base of curated biological knowledge constructed from
publicly available online KBs (e.g. Reactome [56]). RIIG formalism
treats active state of biomarker proteins as manifestation of related
biological mechanisms and recreates a holistic view of their inﬂu-
ence inter-relationships for theranostic purposes. The Methods
section provides a description of the key elements of RIIG formal-
ism and its implementation (more details of the RIIG formalism are
available in Supplementary Materials (SM)).
2. Methods
2.1. RIIG formalism overview
RIIG takes advantage of the vast amounts of curated biomedical
knowledge from publicly available online KBs. First, it turns these
KBs into application-speciﬁc RDF knowledge networks [57] (Fig. 1
Phase 1). In context of morphoproteomics, descriptions of entities
or their interactions (e.g. structure of a small molecule, constants/
coefﬁcients/statistical measures of biochemical reactions), and
auxiliary constructs such as evidence type, data source, and publi-
cation cross-references are ﬁltered out during the process of trans-
formation KBs into KNs (for further explanation see Section 2.2).
Additionally, knowledge from the original KBs is extended through
description logic inference [57] For instance, Resource Description
Framework Schema level inference [58] is used to resolve aliases of
the same biological entity present in different component-KBs
under different names or identiﬁers (for details see Section 2.4).
Second, RIIG introduces an informatics formalism that borrows
ideas from probabilistic causal theory (PCT) [59] and probabilistic
graphical models (PGMs) [60] to infer inﬂuence diagrams (Fig. 1
Phase 2).
Unlike PCT and PGMs, RIIG does not process any probabilistic
data to generate graphical representation of relationships in the
data (e.g. Bayesian Networks). Instead, RIIG formalism establishes
a notion of conditional relevance of nodes representing biological
entities in the RDF knowledge networks. It identiﬁes such relevan-
cies by traversing the paths between the nodes and analyzing the
type of the edges. Essentially, two RDF nodes are considered to
be RDF relevant if a biologically meaningful connection can be
established between these nodes based on the semantic meaning
of the RDF predicates in the path between the nodes. More specif-
ically, if a path between two nodes a and b is active in regard to a
set S of some other nodes, then nodes a and b are considered to be
conditionally RDF relevant in regard to the set S. The active status of
the path (a, b) is deﬁned by the ‘‘ﬂow of information’’. This in turn
is dependent on the presence of so-called collider nodes. A collider
node has two adjacent directional RDF predicates (see Deﬁnition 18
in Appendix B of SM) pointing to this node. If no collider node is
present in the path (a, b), then the path (a, b) is active in regard
to S if and only if it contains no nodes from S. In case there are
Fig. 1. RIIG workﬂow. The left panel consists of RDF triples (shown as triples of s-subject, p-predicate and o-object) of integrated RDF ‘‘mashup’’ KB. During Phase I the KB is
transformed into an application-speciﬁc RDF knowledge network (central panel) by removing information that is not related to a particular application of RIIG (gray circles in
the left panel, see Section 2.2) and extending knowledge through descriptive logic entailments (see Section 2.4). Phase 2 treats clinical data (shown with stars on the right
panel) from IHC studies of biomarker protein expression as manifestation of activated biological pathways and recreates an inﬂuence diagram (right panel) by applying RIIG
formalism on the RDF knowledge network.
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only if all such collider nodes or their descendants (see Deﬁnition
17 in Appendix B of SM) are in S. In-depth description of the con-
cept of RDF relevance is provided in Sections 2.3, 2.4, and Deﬁni-
tions 14, 15, 16, 18, 19 and 21 in Appendix B of SM, which also
provides biological interpretation of RIIG RDF graph patterns. The
details of RDF relevance computation algorithm are provided on
Fig. 4.
Based on the computed conditional relevancies, RIIG leverages
probabilistic constrained-based structure learning algorithms [61],
to generate an inﬂuence diagram. The overall algorithmic roadmap
of the RIIG formalism is presented in Fig. 2.
In the following sections, we discuss basic aspects of the RIIG
formalism, including notions of RDF knowledge network, collider,
active path and relevance. A complete and formal description of
RIIG is included in SM.Input of Entities 
of Interest
Precomputing of RDF paths 
between EOIs
Semantic Mashup 
Knowledgebase
RIIG RDF 
graph RDF pathsRDF, OWL, 
SPARQL  
inference
Fig. 2. RIIG algorithmic roadmap. RIIG begins with specifying entities of interest (EOI) (e
then pre-computes RDF paths and stores them in RDF paths’ array for optimization pu
relevance extraction. To compute RDF paths, the method traverses RIIG RDF knowledge
level inference from semantic ‘‘mashup’’ KB (SMKB). In the next step, the RIIG method
algorithms where conditional independence statements are replaced with RDF relevance
are computed. The end result of the RIIG workﬂow is RDF-induced diagram of relations2.2. RDF knowledge network
An elementary piece of information in an RDF KB is an RDF triple
(Deﬁnition 6 in SM) of the form <subject, predicate, object>. RDF
resources are used as subjects and objects, and RDF properties are
used as predicates of an RDF triple. The RIIG’s deﬁnition of an
RDF KB is stated as a set of RDF triples (Deﬁnition 7 in SM). Since
the object of an RDF triple can be the subject or the object of another
RDF triple, the set of RDF triples of RDF KB forms a graph. In con-
text of RIIG the notion of a transformed RDF graph that we call
RDF knowledge network (KN), is given below:
Deﬁnition (RDF knowledge network). Given an RDF knowledge
base KBRDF and isomorphic mapping functions fn() and fe(), an RDF
knowledge network is a graph GRDF = (NRDF, ERDF) with a set of nodes
NRDF and a set of edges ERDF, for which the following holds:Diagram Induction RDF-induced Infl;uGram
RDF relevance 
extraction
.g. biomarker proteins and biological pathways in case of morphoproteomics). RIIG
rposes because RDF path information can be requested multiple times during RDF
network that is computed on-the-ﬂy through SPARQL queries and RDFS- and OWL-
infers an InﬂuGram by utilizing probabilistic constrained-based structure learning
statements. During this step, RDF collider nodes are identiﬁed and RDF relevancies
hips among EOIs.
B CA D E
B
DA E
C
Fig. 3. Active RDF path examples.
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  2 T; where orSubjo ; orObjo 2 ORo; opPredo
2 OPo : 9ni;nj 2 NRDF ; eðni;njÞ 2 ERDF : ni ¼ fn orSubjo
 
;nj
¼ fn orObjo
 
e ¼ fe opPredo
 
;
where e(x, y) denotes an edge from node x to node y, ORo is the set of
RDF object resources of KBRDF, OPo is the set of RDF object properties
of KBRDF, and T is a set of all RDF triples of KBRDF. This deﬁnition
effectively states that an RDF graph in RIIG formalism is composed
of a subset of RDF triples of an RDF knowledge base KBRDF in which
each triple t has its objects and subjects as RDF object resources and
as its predicates RDF object properties (RDF literals and RDF data
properties are excluded). Furthermore, current algorithmic imple-
mentation of RIIG utilizes predicate ﬁlters that ﬁlter out predicates
that do not carry any application-speciﬁc meaning for the task at
hand but serve as auxiliary constructs by knowledge base providers.
The process of ﬁltering out application irrelevant information is not
strictly formalized by RIIG but rather based on a particular use-case.
In context of morphoproteomics, a theranostic practitioner is usu-
ally interested in an analysis of interplay of proteins and pathways
in general and not in the details of biochemical reactions such as
equilibrium constants and/or a conﬁdence level that a certain
substance exists in vivo. Since such information can be present in
knowledge bases expressed, for instance, by BioPax 2 ontology
(‘‘kPrime’’ and ‘‘conﬁdence’’ classes respectively), we remove it.
However, the removed information can be ‘‘recovered’’ from the
original KB components as needed. For example, if the practitioner
needs to check the data source or evidence type to help in decision-
making, corresponding BioPax data provenance classes can be que-
ried from the KB. So, the actual induction of RIIG diagrams takes
place on such transformed RIIG KN. To do so, RIIG introduces the
notion of RDF relevance in RDF KNs.2.3. RDF relevance
RDF relevance in RIIG formalism is based on the following con-
cepts: (i) i-directional RDF predicates and paths, (ii) RDF collider
and non-collider nodes, and (iii) active RDF paths.
An i-directional RDF predicate (Deﬁnition 14 in SM) is an RDF
object property that semantically expresses the inﬂuence of one
biological entity on the active state (Deﬁnition 13 in SM) of
another. For example, for an enzyme E and a biochemical reaction
BR (RDF protein and RDF interaction respectively in RIIG terminol-
ogy, see Deﬁnitions 9–12 in SM), the ‘‘CONTROLLER’’ RDF object
property of the Biopax 2 ontology [62] can be used to express
the inﬂuence of E on active state of BR using an RDF triple t =
hE, CONTROLLER, BRi. The RDF graph of a knowledge base that
contains the RDF triple t will have a corresponding directed edge.
Letter ‘‘i’’ in the word ‘‘i-directional’’ signiﬁes the fact of passing
directed inﬂuence by an i-directional RDF predicate. A path
pathRDF(nk, nm) between RDF nodes nk and nm is called an
i-directional RDF path if it has at least one i-directional predicate
and whose all i–directional predicates point to the direction to
the node nm (Deﬁnition 15 in SM).RDF collider node is another important concept of the RIIG for-
malism. If an RDF node has two i-directed RDF paths pointing to it,
it is called an RDF collider node. An RDF path that has at least one
collider node is called RDF collider path (Deﬁnition 18 in SM).
RDF collider paths are used by RIIG formalism deﬁne the notion
of active RDF path, which is formulated as follows (for formal def-
inition of active RDF path see Deﬁnition 17 in SM):
Deﬁnition (active RDF path). An RDF path RP is considered active
in relation to a set of RDF nodes S if any of the following two
conditions hold: (i) RP is a non-collider path and no nodes of RP in
are in S; (ii) RP is a collider path and for each collider node in RP
either the collider node is in S or any of its descendants is in S.
For example, on left side of Fig. 3, a non-collider RDF path from
node A to node E is active in relation to an empty set of RDF nodes
and is inactive in relation to any set consisting of nodes B, C, and/or
D. The collider RDF path from node A to node E on the right side of
Fig. 3 is active only in relation to a set that includes nodes B or C
(C being a descendant of B) or both. The path from A to E is consid-
ered to be inactive in relation to any other set of RDF nodes that
does not include B and/or C.
Using the notion of RDF active paths we can now formulate the
concept of RDF relevance as follows (for formal deﬁnition of RDF
relevance see Deﬁnition 21 in SM):
Deﬁnition (RDF relevance). Any two RDF nodes are said to be
conditionally RDF relevant in relation to S, expressed as R(na, nb|S), if
and only if there exists an active path between these two nodes in
relation to S.
The notion of RDF relevance mimics conditional independencies
in probabilistic systems and is used to generate graphical represen-
tation of relationships among biological entities (see Conjectures 1
and 2 in SM). In the current RIIG implementation, we used con-
straint-based structure learning PC algorithm [61] that we adapted
from TETRAD package [63].
2.4. Inferring RDF-induced inﬂuence links
To infer RDF-induced inﬂuence links from the RDF KN of
Semantic Mashup KB (SMKB) (see SM) we utilize probabilistic
structure learning algorithms PC (named after Peter Spirtes and
Clark Glymour) [61] implemented in TETRAD package [63] and
Inferred-Causation ICS [64] implemented in Weka [65]. In all cases
we replace the function in these libraries that tests for conditional
independence with RIIG’s IsRDFIrrelevant() function, the algorithm
ﬂow of which is presented in Fig. 4.
The IsRDFRelevant() function determines RDF relevance
between any two RDF nodes x and y in relation to a set Z of some
other RDF nodes by analyzing RDF paths between these nodes. If it
ﬁnds at least one active RDF path (see Deﬁnition 19 in SM), the cor-
responding RDF nodes are considered to be RDF relevant. The RDF
relevance information is then used to induce the structure of rela-
tions among EOIs.
Another key part of the RIIG formalism is a function that ﬁnds a
path between two RDF nodes. We extend the RDF path search
Fig. 4. Pseudo-code of the IsRDFIrrelevant() function.
B2
B3
B1
B4
B5
B6B7
s-p-o o-p-
s
s-p-o
s-p-o
o-p-s
o-p-s
s-p-o
RDF Path 2
RDF Path 1
Fig. 5. Multiple paths between two RDF nodes.
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tion implements a Breadth First Search (BFS) algorithm. However,
it searches for possible paths between nodes only in the direction
from subject to object. To understand that let us look at RDF paths
in Fig. 5.
In the RDF path B1–B2–B3–B4–B5, the object of each triple is the
subject of the next adjacent triple. For example node B2 is the object
of the triple B1–B2 and the subject of the triple B2–B3 and so on.
Note that direction of the edges in Fig. 5 neither corresponds to
i-directionality of RDF predicates nor indicates the direction of
inferred RDF inﬂuence links. It merely helps to determine subject
and object of the triple (the subject is adjacent to the tail of the edge
and object to its arrowhead). The Jena’s path search function was
not designed to ﬁnd paths where the object of a triple can serve
as the object of adjacent triple (e.g. RDF Path 2 B1–B2–B7–B6–B5in Fig. 5). We extend this function to accommodate search for such
paths. It however dramatically increases complexity of the search,
which is one of the directions of our future research. In this work
we limit search space of the graph and demonstrate the utility of
the proposed method on a subset of SMKB.
Different RDF nodes in the knowledge base can represent the
same biological entity. When checking if an RDF node A is a mem-
ber of the set S, we also need to check all other nodes that repre-
sent the same biological entity as the node A to see if any of
them is in S. For instance, in Fig. 6 node B5 is not in S, but node
B6 (let us call it alias of B5) that represents the same biological
entity (through RDF predicate ‘‘XREF’’ of BioPAX 2 ontology) is in
S. We will, therefore, consider that node B5 is a member of S.
Checking if an RDF node A is a member of the set S requires
ﬁnding all aliases of the node A. To optimize SPARQL query opera-
tions, we use RDF/OWL level inference and pre-compute entail-
ments of the set S to get an expanded set S⁄. The entailments
include all aliases of all nodes in S. We then check each RDF node
against the expanded set S*. Fig. 7 illustrates this process. The set S*
includes node B5 as an entailment. The entailments are structurally
shown as a part of the ‘‘Dynamic KB and Rule bases’’ components of
(see SM).
2.5. RIIG ‘‘toy example’’
Here, we illustrate the RIIG formalism’s workﬂow using a toy
example. Panel A in Fig. 8 presents a hypothetical RDF KB. The
KB consists of ontology and instance data, which are both stored
B2
B3B1 B4
B5 B6
B6
S
XREF
Fig. 6. RDF graph without entailments.
B2
B3B1 B4
B5
S*
B5 B6
XREF
Fig. 7. RDF graph with entailments.
D. Shin et al. / Journal of Biomedical Informatics 52 (2014) 394–405 399as RDF triples. The ontology speciﬁes biological meaning of the
entities of the KB. For instance, RDF object resources ‘‘PROTEIN’’
and ‘‘PATHWAY’’ correspond to biological entities of a protein
and a pathway, and RDF predicates ‘‘COMPONENTS’’ and ‘‘CON-
TROLLER’’ represent biological relationship of a component of a
protein complex with the protein complex and controlling entity
of a biochemical reaction with the biochemical reaction, respec-
tively. Names of the RDF instance entities are composed from the
preﬁxes and literals. For example, ‘‘PrA’’ reads as ‘‘PROTEIN A’’,
and ‘‘CT3’’ reads as ‘‘CONTROL 3’’. The proteins, protein complexes
and pathways of a morphoproteomic study are represented by RDF
Entities of Interest (EOI). In this toy example we have protein
‘‘PrB’’, protein complex ‘‘PcA’’ and pathways ‘‘PaC’’, ‘‘PaD’’, and
‘‘PaE’’.
The ﬁrst step in RIIG method is induction of an RDF KN from the
RDF KB (Panel B in Fig. 8). In the current RIIG implementation, RDF
KNs are mere logical constructs and do not have a persistent form.
They are generated on-the-ﬂy by: (i) ﬁltering out RDF KB elements
that do not carry any biological meaning, (ii) resolving aliases, and
(iii) expanding knowledge base through description logic inference
(see more in SM). We have to note here that the resulting RDF KN
represents a completely new source of knowledge that has two
properties that make it signiﬁcantly different from the original
RDF KN, namely: (i) absence of biologically irrelevant entities
and (ii) augmentation of the original body of knowledge. Such
RDF KN aggregates, uniﬁes and augments biologically relevant
information frommultiple KBs. RIIG uses this RDF KN to mine rela-
tionships between biomarkers proteins and biological pathways.
RDF KN allows application of graph algorithms for path tra-
versal among RDF object resources, which is used by RIIG to extract
RDF relevance statements among EOIs (Panel C in Fig. 8). RDF
relevance relations are formalized by RIIG method and model
conditional independence relationships of probabilistic systems
(Conjecture 1 in Appendix B of SM). For instance, the statement
‘‘R(PcA, PaC)’’ means that the protein complex ‘‘PcA’’ is uncondition-
ally RDF relevant to the RDF pathway ‘‘PaC’’. That means that the
biological activities of these two entities are ‘‘related’’ regardless
of the active state (see Deﬁnition 13 in SM) of all other elements
in the RDF KN. Another example is the RDF relevance statement
‘‘R(PrB, PaE|PaC)’’. This statement says that the protein ‘‘PrB’’ is
RDF irrelevant to the pathway ‘‘PaE’’ given that we know the active
state of the pathway ‘‘PaC’’. In other words, it means that if we
know the biological status of the pathway ‘‘PaC’’, the knowledge
about the status of the pathway ‘‘PaE’’ becomes irrelevant to infer
the status of the protein ‘‘PrB’’.One of the central ideas in RIIG formalism is that we can use
probabilistic constraint-based structure learning algorithms where
conditional independence statements are replaced by RDF
relevance statements (Conjecture 2 in Appendix B of SM) to induce
a set of RDF inﬂuence links. Such links model causal links in a
probabilistic setting [59]. Panel D in Fig. 8 shows three steps of this
process. In Step 1 a fully connected graph with EOIs as its nodes is
generated. Step 2 eliminates edges using RDF relevance state-
ments. In Step 3 the direction of relationships are determined.
Steps 1, 2 and 3 are essential parts of structure-learning algorithms
such as PC algorithm [61]. In RIIG formalism, RDF inﬂuence links are
marked with double arrows in an RDF-induced InﬂuGram. Such
diagram can be used for morphoproteomic analysis.
3. Results and discussion
3.1. RIIG assessment
The goal of the RIIG method assessment was twofold: (i) vali-
date the ability of RIIG framework to recover a set of predeﬁned
inﬂuence links from a ‘‘synthetic’’ data set, and (ii) compare the
performance of RIIG method implementation with a naïve Monte
Carlo process. Details on RIIG assessment protocols can be found
in SM.
In the ﬁrst case, we simulated a hypothetical clinical case where
we predeﬁned a priori inﬂuence relations between biomarker pro-
teins and biological pathways. These relations were encoded into a
synthetic RDF knowledge base according to the BioPAX 2 ontology
(for details see SM). We ran RIIG algorithm implementation multi-
ple times and noted the percentage of recovered links as well as
the number of any new links that may arise due to the inter-
relationships established among the entities of the synthetic KB.
In 50 runs of RIIG, we could recover anywhere from 60% to 90%
of the number of predeﬁned links and could get 5–10% of new
inﬂuence links. We noted that when the ratio of predeﬁned links
to the overall number of EOIs became smaller, RIIG could recover
more predeﬁned links and get fewer new links. This could be read-
ily explained as follows. When the ratio is small, the probability of
two or more predeﬁned links to ‘‘disrupt’’ corresponding RDF col-
liders due to random adjacency is lower. That enables RIIG to
recover more predeﬁned links. But at the same time, the chance
of spontaneous appearance of new RDF colliders is also lower,
which results in a lower number of non-predeﬁned, new links.
In the second case, we compared the performance of RIIG to
infer links with a Naïve Monte Carlo sampling. We used RIIG on
a set of EOIs to infer the RIIG links. For each pair of these EOIs
we computed joint frequency of their appearance in PubMed
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Fig. 8. ‘‘Toy’’ example of RIIG formalism workﬂow.
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RIIG and PubMed-derived links. The process was repeated 50
times. We then compared these numbers with the counts of
matches and mismatches of PubMed pairs with uniformly
randomly sampled links from the set of EOIs. The mean values of
matches between RIIG and PubMed and between Naïve Monte
Carlo were 14.22 and 7.61 respectively. Levene’s tests showed that
the data fail to satisfy homoscedasticity requirement with P-valueof 0.04559 with for alpha conﬁdence level of 0.05. The normality
assumption violation was demonstrated by Shapiro–Wilk test with
p-Values of 0.02016 and 0.00044 for matches between RIIG and
PubMed and between Naïve Monte Carlo and PubMed respectively.
We have therefore decided to use non-parametric tests. Kruskal–
Wallis rank sum test was signiﬁcant with p-Value < 0.001, which
allowed us to conclude that RIIG inferred links statistically better
match ﬁndings from PubMed abstracts.
D. Shin et al. / Journal of Biomedical Informatics 52 (2014) 394–405 4013.2. Validation of RIIG on clinical morphoproteomic cases
We have run experiments with the proteins and pathways from
two morphoproteomic cases reported by pathologists in [20,67,18]
to see if RIIG can reveal the same morphoproteomic portraits.
In the ﬁrst case, the pathologists used morphoproteomics to
ﬁnd alternate drug targets for a patient who did not respond to a
conventional chemotherapy. They opted to use a Bortezomib drug,
a proteasome inhibitor, in a combination with another drug Dexa-
methasone, to treat relapsed Acute Lymphoblastic Leukemia (ALL).
The goal was to construct a morphoproteomic diagram related to
the case’s biochemical processes in such a way that appropriate
drug target can be identiﬁed. After conducting IHC tests for paraf-
ﬁn-embedded tissue, correlative expression of AKT, NF-kappa-B
and BCL-2 proteins was revealed. The next task was to infer the
biological circuitries that were manifested by the expression of
these proteins. After analysis of several signal transduction path-
ways, the pathologists [17,20] came to the conclusion that an
anti-apoptotic mechanism had been activated in this case, which
led to the disruption of programmed cell death and therefore abnor-
mal cell proliferation. Speciﬁcally, the activation of AKT pathway
led to the activation of the of NF-kappa-B protein that in turn
resulted in up-regulation of BCL-2 protein, which is known to be
an anti-apoptotic agent. To test our approach, we ran the RIIG
implementation for BCL-2, AKT and NF-kappa-B proteins and a
set of signal transduction pathways that included AKT and
NF-kappa-B pathways. The resulted diagram of inferred inﬂuence
links is presented in Fig. 9A).
As it can be seen from Fig. 9A), the algorithm has identiﬁed
inﬂuence of the AKT pathway to the expression of RELA protein,
which is a subunit of NF-kappa-B protein. Our method has also cor-
rectly positioned BCL-2 downstream from NF-kappa-B signaling
pathway, which explains the expression of its main effector RELA
(NF-kappa-B) protein.
The second morphoproteomic case [17,18] involved a study of
Rapamycin drug as a potential treatment forMesenchymal Chondro-
sarcoma. In this case IHC studies revealed cytoplasmic expression
of phosphorylated AKT (p-AKT) and mTOR (p-mTOR) proteins as
well as nuclear expression of phosphorylated p70 S6 kinase
(p-p70S6K). After morphoproteomic analysis the conclusion was
that p-AKT causes an activation of p-mTOR, which in turn phos-
phorylates p-p70S6K. Since mTOR is a molecular target of Rapamy-
cin, it was suggested this drug be used to inhibit mTOR activity and
therefore disrupt activation of p70S6K and consequent G1 cell cycle
progression in malignantMesenchymal Chondroblasts. To check RIIG
inference in this case we ran the algorithm for AKT1, FRAP1 (alias
for mTOR) and RPS6KB1(alias for p70S6K) proteins and AKT and
mTOR pathways. The morphoproteomic diagram with inferredAKT1
NF-KB signaling pathway
AKT signaling pathway
RDF-INDUCED INFLU
(A)
RELA
BCL2
FRAP
(B)
RPS6KB1
Fig. 9. RIIG-generated diaginﬂuence links is presented in Fig. 9 B). AKT protein is known to
be a key modulator of AKT pathway whose activity is closely
related to mTOR pathway [68–70]. This fact is shown by an
inﬂuence link on our diagram in Fig. 9B). The second molecular
mechanism is represented by an inﬂuence link from FRAP1 to
RPS6KB1 proteins. It was reported in the literature that mTOR
signaling pathway regulates FRAP1 (mTOR) protein kinase
[16,27,67,71–76], which makes these two entities ‘‘interchange-
able’’ in the context of the overall workﬂow of involved proteins
and pathways. This demonstrates that revealed by RIIG relation-
ships conﬁrm the ﬁndings described in [18,70,77–81].
3.3. Discovering alternative therapeutic targets
Next, we tested RIIG application to facilitate the development of
novel means of treating malignancies that are advanced and resis-
tant to the usual therapeutic modalities. Generally, these patients
have already undergone treatment with multiple standard drug
regimens and perhaps even experimental drug trials. It is in such
cases that morphoproteomics provides essential information for
personalized medical care based on the interpretation of ﬁndings
in the biopsies of the patients own tumors in contrast to basing
therapy on that general class of tumors. However, the linkage of
visually observable tumor features to potentially effective chemo-
therapy requires a deep, as well as broad, knowledge of both can-
cer genomics and pharmacogenomics, which is well beyond the
capability of most pathologists. Nonetheless, when provided with
access to an extensive genomics database and a rational approach
to information retrieval based on cellular pathways and protein
interactions, a pathologist or oncologist can leverage his/her basic
knowledge of disease to obtain more speciﬁc and relevant data
through their own iterative interactions with the knowledge base.
For example, we consider the treatment of squamous cell carci-
noma (SCC) which is a very common malignancy affecting an
extensive variety of tissues. Feng et al. [17,71,73,75,82–85] have
described their experience in marshalling proteomic evidence for
the unconventional treatment of cervical squamous cell carcinoma
by identifying over-expression of proteins within the epidermal
growth factor receptor (EGFR) and the mammalian target of rapamy-
cin (mTOR) signaling pathways. These pathways were evaluated in
view of their known frequent involvement in malignancies as well
as their susceptibility to pharmacologic inhibition. The EGFR
pathway may be down regulated with erlotinib and mTOR with
an analogue of rapamycin, temsirolimus. The authors conclude that
such a regimen would be reasonable for the treatment of early
stage cervical SCC. In order to investigate the potential for RIIG
to contribute new knowledge relevant to the treatment of SCC in
general, we used RIIG to infer other possible protein interactionsENCE DIAGRAMS 
RASA1
EGFR signaling pathway
(C)
STAT1
JAK1
MTOR signaling pathway
AKT signaling pathway
STAT3
EGFR
rams for clinical cases.
Fig. 10. RIIG-generated diagrams for general case of ALL.
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et al. [17,86].
Starting with a simpliﬁed role of the EGFR pathway in the origi-
nal Feng’s morphoproteomic diagram we used RIIG to explore
alternative therapeutic venues. Several proteins were queried lead-
ing to the identiﬁcation of interactions between JAK1, RASA1,
STAT1 and STAT3 (signal transducers and activators of transcrip-
tion 3), which are components of the JAK-STAT signaling pathway.
To check protein and pathway relationships discovered by our
method, a systematic literature review was conducted using a set
of queries for PubMed searches (see SM). The interactions that
have been revealed by our approach are shown Fig. 9C. Some of
the important points derived from RIIG that can lead to a new drug
therapy are as follows: (i) the activation and over-expression of the
transcription factor STAT3 plays an important role in the SCC geno-
mic apparatus, (ii) the activation of this protein may be identiﬁed
by the presence of the phosphorylated form and its translocationfrom the cytoplasm to the nucleus, (iii) STAT3 expression has been
demonstrated to be down regulated by several pharmacologic
agents. These agents have shown some experimental effectiveness
in other malignancies including breast carcinoma and chronic
myeloid leukemia.
3.4. Discovering novel inﬂuence links in Acute Lymphoblastic
Leukemia
A hypothetical medical setting considered here is a situation of
attempting to devise new therapeutic options for patients with a
malignant disease refractory to conventional chemotherapy. Acute
Lymphoblastic Leukemia (ALL) was chosen as a representative dis-
ease. Based on practical knowledge obtained through practice in
the subspecialty of hematopathology, the medical researcher
selected 29 pathways and 22 proteins, which have been generally
related to ALL in the medical literature.
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ways in regard to treatment of ALL. The proteins/pathways were
then processed by RIIG and a network of inﬂuence links between
these entities was generated. Only directed links were retained.
Inﬂuence links were identiﬁed between 28 of the 29 pathways
(p-53 was the exception), but only 6 of the 22 proteins. We then
conducted a systematic literature review to retrieve information
related to potential new treatments. It was done through PubMed
search queries based on terms derived from the interactions of
proteins and pathways as generated by RIIG.
The RIIG-generated diagrams allow the identiﬁcation of
upstream and downstream pathways, that is to say, pathways that
activate other pathways versus those that are activated by
other pathways. This provides a good perspective for identifying
pathways that might be blocked through the manipulation of other
effector pathways. For example, the caspase pathway is seen to be
activated by 7 of the pathways while activating none itself
(Fig. 10a). Thus, this provides an accurate representation of the
caspase pathway’s role as the ﬁnal-end stage effector of cell death
as initiated by multiple other pathways. Similarly, the TGF-beta
signaling pathway is also activated through 7 upstream pathways
while not activating any pathways in our schema (Fig. 10b). This
is consistent with the signaling function of this pathway that leads
more or less directly to the activation of transcription factors
rather than other pathways. Similar observations may be made
for the IL-7 and EIF2 pathways (Fig. 10c and d).
On the other hand, the platelet-derived growth factor pathway is
known to support a variety of cellular mechanisms including cell
proliferation and survival, deposition of extracellular matrix and
tissue remodeling. This is reﬂected in our model by a graph showing
the activation of 7 other pathways by the PDGF pathway (Fig. 10e).
The ability of PDGF ligands to activate JAK1/2 through tyrosine
phophosphorylation was shown in an older paper by Vignais et al.
[87] thus conﬁrming the interaction of the PDGF pathway with
JAK2 as identiﬁed in our graph of the JAK network (Fig. 10d).
RIIG serves as an effective ﬁlter for literature information
extraction by focusing attention on speciﬁc interactions of proteins
and pathways. This preprocessing step saves investigational time
by limiting the search to interactions known by the knowledge
base although perhaps not known to the investigator. This helps
to identify new, or recently reported, knowledge in a medical
setting. For example, a sub-network involving JAK1/2 and CD79a
along with several upstream pathways was generated by RIIG.
Literature searches base on this sub-network yielded several
potential therapeutic agents as well as several recently reported
protein interactions not yet contained within reference protein
interaction databases.
Using RIIG we could also identify some interesting protein
interactions involved in ALL. AKT1 is shown to interact with
CD79a in our network, but this interaction is not reported in the
NCBI Gene database. Nonetheless, a recent article in Blood reports
the recruitment of AKT1 to B-cell receptor activation complexes
(CD79a) in chronic lymphocytic leukemia [88].
Next, we looked into the identiﬁcation of potential therapeutic
interventions. A number of therapeutic agents potentially effective
against ALL were readily identiﬁed by focusing the literature
search on the proteins JAK1 and JAK2. Bellucci et al. [89] found that
gene silencing of JAK1/2 and the use of the small molecule inhibi-
tors JAK inhibitor 1 and AG-490 against these proteins resulted in
increased natural-killer cell mediated lysis of a variety of tumor
types. Another article in Neoplasia [90] showed that the JAK1/2
inhibitor INCB16562 is effective against multiple myeloma.
Another drug potentially effective against ALL was identiﬁed
through the interaction of the IL7 pathway with JAK1/2. In this
instance, an article in Blood [91] showed that a BET bromodomain
inhibitor, JQ1 which down regulates IL7, was potentially effectivein certain high risk types of ALL with CLRF2 rearrangements.
Maude et al. [92] studied xenograft models of ALL cases with the
CLRF2 rearrangement as well as JAK1/2 point mutations and JAK2
fusion genes which resulted in hyperactive JAK/STAT signaling.
Their data demonstrated in vivo efﬁcacy of ruxolitinib in these
cases.4. Conclusion, limitations and future directions
Basic science discoveries coupled with tremendous advances in
‘‘omics’’ technologies have triggered a paradigm shift in today’s
biomedicine. The ideas of translational and personalized medicine
are viewed as solutions to improve patient care by bringing
state-of-the-art biomedical knowledge into clinical setting to
combat disease complexity and heterogeneity [3]. However, as it
was pointed out a decade ago by Sung et al. [2] the two major
challenges of clinical translation enterprise are translation of basic
sciences discoveries into clinical research and translation from
outcomes of clinical research to the bedside. In this context RIIG
provides a solution to overcome the roadblocks of translational
science by: (i) utilizing ‘‘conﬁrmed’’, curated knowledge of relevant
biological processes, (ii) recreating a mechanistic schema of inﬂu-
ence relationships between disease-associated genes and molecu-
lar pathways based on clinical data (biomarker proteins), and (iii)
presenting the results in a fashion that allows quick interpretation
by clinicians. Moreover, knowledge exploration through RIIG may
effectively lead to the discovery of clinically useful information
in regard to treatment of disease of all forms. Furthermore, RIIG
can potentially be used to generate new hypotheses that will need
to be conﬁrmed by experimental studies. In this regard, RIIG closes
the loop from bedside to basic science research.
In context of morphoproteomics, RIIG provides a solution to the
limitation of individual expert’s knowledge of biochemical pro-
cesses by leveraging computerized knowledge bases. For instance,
a pathologist may have knowledge only about limited number
anti-apoptotic mechanisms to make therapeutic recommendation
in a particular patient case. Such knowledge may not match the
real biological mechanisms of anti-apoptosis taking place in the
case, leading to complications and adverse side effects in terms
of clinical outcomes. RIIG allows searching against any number of
anti-apoptotic pathways known so far to biomedical science. But
unlike traditional retrieval methods, RIIG rearranges the facts into
the coherent ﬂow of events through directed inﬂuence relations,
which helps to pinpoint effective drug targets with the minimal
number of known side effects.
Experiments with the RIIG implementation showed its great
potential not only for the morphoproteomics area but also for
the biomedical ﬁeld in general. However, at present, it is possible
to run RIIG only on a limited subset of SMKB due to the perfor-
mance issue of graph traversal algorithms. To overcome this and
to explore other venues for the improvement, we have identiﬁed
the following future research directions: (i) improving inﬂuence-
induction algorithm (e.g. test other structure learning algorithms),
(ii) implementing RIIG on high-performance parallel computing
platform, (iii) conducting extensive experiments with clinical
cases, (iv) expanding therapeutic part of SMKB by including addi-
tional drug information and incorporate small molecule inhibitors
and protein-therapy agents data, (v) designing human-in-the-loop
computational framework for generating effective combinatorial
therapeutic strategies.Acknowledgments
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